1. Yap,
Y.S.,
et al.,
The NF1 gene revisited - from bench to bedside. Oncotarget,
2014.
5(15): p.
5873-92.
2. Ferner,
R.E.,
et al.,
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet,
2007.
44(2): p.
81-8.
3. Ducatman,
B.S.,
et al.,
Malignant peripheral nerve sheath tumors.
A clinicopathologic study of 120 cases. Cancer,
1986.
57(10): p.
2006-21.
4. Evans,
D.G.,
et al.,
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet,
2002.
39(5): p.
311-4.
5. Combemale,
P.,
et al.,
Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS One,
2014.
9(2): p.
e85954.
6. Canavese,
F.
and J.I.
Krajbich,
Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop,
2011.
31(3): p.
303-11.
7. Wu,
J.S.
and M.G.
Hochman,
Soft-Tissue Tumors and Tumorlike Lesions: A Systematic Imaging Approach. Radiology,
2009.
253(2): p.
297-316.
8. Piscitelli,
O.,
et al.,
Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning. Dev Med Child Neurol,
2012.
54(1): p.
49-51.
9. Gayre,
G.S.,
et al.,
Long-term visual outcome in patients with anterior visual pathway gliomas. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,
2001.
21(1): p.
1-7.
10. Omuro,
A.
and L.M.
DeAngelis,
Glioblastoma and other malignant gliomas: A clinical review. JAMA,
2013.
310(17): p.
1842-1850.
11. Broski,
S.M.,
et al.,
Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiology,
2016.
45(8): p.
1097-1105.
12. Demehri,
S.,
et al.,
Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol,
2014.
35(8): p.
1615-20.
13. Gatidis,
S.,
et al.,
Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous (1)(8)F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to (1)(8)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Invest Radiol,
2016.
51(1): p.
7-14.
14. Lu-Emerson,
C.
and S.R.
Plotkin,
The Neurofibromatoses.
Part 1: NF1. Rev Neurol Dis,
2009.
6(2): p.
E47-53.
15. Chawla,
S.C.,
et al.,
Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol,
2010.
40(5): p.
681-6.
16. Boellaard,
R.,
et al.,
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging,
2015.
42(2): p.
328-54.
17. Schafer,
J.F.,
et al.,
Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology,
2014.
273(1): p.
220-31.
18. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP,
1998.
28(3): p.
1-126.
19. Vanderhoek,
M.,
S.B.
Perlman,
and R.
Jeraj,
Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med,
2012.
53(1): p.
4-11.
20. Neubauer,
H.,
et al.,
Diagnostic Value of Diffusion-Weighted MRI for Tumor Characterization,
Differentiation and Monitoring in Pediatric Patients with Neuroblastic Tumors. Rofo,
2017.
189(7): p.
640-650.
21. Billiet,
T.,
et al.,
Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. Neuroimage Clin,
2014.
4: p.
649-58.